Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
- Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trial
- Clinical responses seen in patients with favored and less favored baseline characteristics
- T cell activation observed post-treatment in tumors of responding patients
Oslo, September12, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for the treatment of cancer, announced today the publication of data from its phase I melanoma trial in Journal of Translational Medicine.
The clinical data give details of potential additional benefit in the treatment of patients with malignant melanoma from using the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor ipilimumab.
The new data demonstrated highly positive clinical outcome signals. Vaccine-induced immune responses were apparent in 91% of evaluable patients, with strong T cell proliferation demonstrated in peripheral blood, and vaccine-related T cell receptor clones detected in blood and in tumor biopsy. Patients who responded clinically to treatment with UV1 and ipilimumab, also demonstrated an increase in the tumor interferon-gamma signature, a generally accepted predictor for the efficacy of checkpoint inhibitors.
The research team observed clinical responses to the UV1-ipilimumab combination not only in patients with baseline characteristics of high tumor immunogenicity (‘hot’ tumors) but also in patients without (‘cold’ tumors). This breadth of response is noteworthy since ’cold’ tumors are more difficult to treat with checkpoint inhibitors, suggesting that the addition of UV1 vaccination may extend clinical efficacy against these tumor types.
These clinical data further expand upon the previously published safety and feasibility findings from an open-label phase 1/2a clinical trial (NCT02275416) of the combination of UV1 with the CTLA-4 checkpoint inhibitor, ipilimumab. The combination of UV1 and ipilimumab produced an overall response rate (ORR) of 33%. The median progression-free survival (mPFS) among patients treated with UV1 and ipilimumab was 6.7 months, and the median overall survival (mOS) was 66.3 months.
Ultimovacs’ phase II trial, INITIUM, evaluates the combination of the UV1 vaccine combined with both ipilimumab and the PD-1 inhibitor, nivolumab, in the first-line treatment of patients with advanced malignant melanoma. Ultimovacs completed enrollment in INITIUM in June 2022. Topline progression-free survival data from INITIUM are expected in H1 2023.
The new data were published in the Journal of Translational Medicine (JTRM), an open access, peer-reviewed journal. The link to the article can be found on the Company’s website.
Ellingsen, E.B., Bounova, G., Kerzeli, I. et al. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. J Transl Med 20, 419 (2022). https://doi.org/10.1186/s12967-022-03624-z
About the phase I trial with UV1 and ipilimumab in malignant melanoma
This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in twelve patients with metastatic melanoma. The trial was an open-label, single-center phase I/IIa study. Eligible patients had unresectable metastatic melanoma. Patients were followed up for progression-free survival (PFS) and overall survival (OS).
The U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for UV1 for the treatment of stage IIB – IV melanoma, and Fast Track designation in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab. Ultimovacs is currently evaluating UV1 as add-on therapy to ipilimumab and nivolumab as first-line treatment for unresectable or metastatic melanoma in a Phase II study named INITIUM.
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program in five cancer indications enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types, in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Phone: +47 908 92507
Anne Worsøe, Head of Investor Relations
Phone: +47 906 86 815
Mary-Ann Chang, LifeSci Advisors
Phone: +44 7483 284 853
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Turning the Tables on Non-Productive Screen Time: Game On, Kids!1.12.2022 18:31:34 CET | Press release
LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- A new app, GenMove, released by app developer G13R Ltd, in collaboration with the World Health Organization, combines artificial intelligence (AI) and the selfie camera to create a fun and playful gamified exercise experience. GenMove aims to get more children up off the couch and moving and, in doing so, turn the tables on the sedentary lifestyle that is largely driven by more and more screen time. Any parent knows that sinking feeling when they try to pry their children away from their phones, tablets, and computer screens. It's like preparing for battle. The addictive tendencies and impacts of too much screen time are undeniable. The GenMove app literally puts its players in the game - through AI body tracking - and provides a high-intensity exercise experience, encouraging its players to coordinate their body movement to control their progress through a series of games and levels. The GenMove app allows its players to self-regulate the inte
Vantiva Q3 announcement1.12.2022 18:00:00 CET | Press release
Press Release VantivaQ3 announcement GUIDANCE IS CONFIRMED ADJUSTED EBITDA1OF €50 MILLION IN Q3, UP 40% yoy SOLID REVENUE GROWTH Paris (France), December 1st, 2022 Vantiva (Euronext Paris: VANTI; OTCQX: TCLRY) Following the spin-off of Technicolor Creative Studios (TCS), Vantiva now comprises two separate business segments, each with solid fundamentals and leading positions in their respective markets: Connected Home and Supply Chain Solutions. Vantiva achieved 45% growth in revenue in the quarter, achieving €765 million (+27.1% at constant exchange rate) and driven largely by performance of the Connected Home division, which continues to enjoy strong demand coupled with improved components availability. Adjusted EBITDA amounted to €50 million (+40%), representing 6.5% of revenues (6.8% in Q3 2021). Despite challenging market conditions, including an inflationary environment, Vantiva has increased its adjusted EBITDA by €14 million. The margin dilution in the quarter came mostly from a
Iveco Group announces Senior Leadership Team changes1.12.2022 18:00:00 CET | Press release
Turin, 1st December 2022. Iveco Group N.V. (MI: IVG) today announces the appointment of Angela Qu as Chief Supply Chain Officer and Ángel Rodríguez Lagunilla as Chief Manufacturing Officer, effective immediately. Angela Qu has over 25 years of experience in manufacturing, supply chain, procurement and management consulting. In 1994, Ms. Qu was appointed by Siemens to develop greenfield manufacturing sites in China. She then headed Global Sourcing at Leybold Optics, later acquired by Bühler Group. She joined ABB in 2005, where she worked in Germany and Switzerland with increasing responsibilities, mainly in Supply Chain and ultimately leading the function at global level. In 2019, Ms. Qu was appointed Chief Procurement Officer of Lufthansa Group and was also a member of the Supervisory Board of Lufthansa Cargo. Ms. Qu holds an MBA in Supply Chain Management from ETH Zurich, Switzerland, she is currently an independent Board Director for Gurin Energy and DANX Carousel and a member of the
Rovio Entertainment Corporation: Repurchase of own shares on 1 December 20221.12.2022 17:45:00 CET | Press release
Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 1.12.2022 at 18.45 EETRovio Entertainment Corporation - Repurchase of own shares on 1.12.2022Rovio Entertainment CorporationIn the Nasdaq HelsinkiDate1.12.2022Exchange transactionBUYShare trading codeROVIOAmount, shares35430Average price/share, EUR6,095207Total cost, EUR215953,18Rovio now holds a total of 6 453 043 shares including the shares repurchased on 1.12.2022On behalf of Rovio Entertainment CorporationOP Corporate Bank PLC Further information: Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 RovioIR@rovio.com Distribution: Nasdaq Helsinki Ltd Key media www.rovio.com About Rovio: Rovio Entertainment Corporation is a global mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 5 billion times. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainment, a
Coloplast A/S - Announcement no. 14/2022 - Articles of Association1.12.2022 17:33:41 CET | Press release
Articles of Association for Coloplast A/S as adopted at the Annual General Meeting of Coloplast A/S held today, 1 December 2022 are enclosed. Our mission Making life easier for people with intimate health care needs Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us Our vision Setting the global standard for listening and responding For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: firstname.lastname@example.org Kristine Husted Munk Sr. Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: email@example.com Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: firstname.lastname@example.org Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announ